 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ZL-1218 / ZAI Lab
Enrollment closed, Metastases: KEYNOTE-F22: A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Oct 22, 2024
P1, N=60, Active, not recruiting, Sponsor: Zai Lab (Hong Kong), Ltd.
Recruiting --> Active, not recruiting
- ZL-1218 / ZAI Lab
Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor (Section 50) - Mar 5, 2024 - Abstract #AACR2024AACR_5228;
Recruiting --> Active, not recruiting Abstract is embargoed at this time.
- ||| ZL-1218 / ZAI Lab
New P1 trial, Metastases: KEYNOTE-F22: A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - May 16, 2023
P1, N=60, Recruiting, Sponsor: Zai Lab (Hong Kong), Ltd.
- ZL-1218 / ZAI Lab
ZL-1218 targets the most suppressive intratumoral Treg subpopulation to avoid peripheral toxicities (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1702;
Conclusions These findings suggest that ZL-1218 antibody may deliver optimal tumor-targeted Treg depletion in the clinic while limiting peripheral toxicities to avoid autoimmune response. Ethics Approval The study was approved by IACUC committee in Zai Lab (US) LLC (Protocol approval number 2020-11_1).
- ZL-1218 / ZAI Lab
ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells (La Nouvelle Orleans C, Convention Center) - Mar 9, 2022 - Abstract #AACR2022AACR_2008;
We are currently exploring the significance of these distinct populations and the impact of ZL-1218-mediated depletion of both CCR8 high- and CCR8 low-expressing subsets in multiple indications. Together, these data support the advancement of ZL-1218 into clinical evaluation as a novel therapeutic candidate to treat human solid tumors.